Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736931 · ClinicalTrials.gov registry record · Phase 1
Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam
A Phase 1 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00736931 is a Phase 1 study that has completed, run by UCB Pharma. The registered enrollment target is 20 participants.
The verdict
NCT00736931, a Phase 1 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam
Interventions
- OTHER placebo
- DRUG Brivaracetam
- DRUG levetiracetam
- DRUG lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736931
The ClinicalTrials.gov registry entry for NCT00736931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00736931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00736931 about?
NCT00736931 is a clinical study titled "Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam". The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam
What is the current status of trial NCT00736931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-07. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00736931?
The interventions under investigation include: placebo (OTHER), Brivaracetam (DRUG), levetiracetam (DRUG), lorazepam (DRUG).
Who is sponsoring clinical trial NCT00736931?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.